Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05236114 · ClinicalTrials.gov registry record
GEMINI-NSCLC: NSCLC Biomarker Study
A clinical trial of Non-Small Cell Lung Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 20
- Study locations
NCT05236114: Recruiting study of Non-Small Cell Lung Cancer, sponsored by Tempus AI.
NCT05236114 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 1,200 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05236114, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (20)
Illinois
- Southern Illinois Hospital Services - Carterville
- Cancer Care Specialists of Illinois - Decatur
- Northwestern University - Evanston
- Hope and Healing Cancer Services - Hinsdale
- OSF Saint Anthony Medical Center - Rockford
California
- MemorialCare - Fountain Valley
- Cancer and Blood Specialty Clinic - Los Alamitos
- UCLA - Los Angeles
Florida
- Clermont Oncology Center - Clermont
- Woodlands Medical Specialists - Pensacola
Georgia
- Morehouse School of Medicine (MSM) - Atlanta
- Piedmont Healthcare - Atlanta
Maryland
- University of Maryland - Baltimore
- Johns Hopkins University - Baltimore
Alabama
- Alabama Oncology - Birmingham
Arkansas
- Mercy Clinic Oncology - Fort Smith - Fort Smith
Connecticut
- Eastern CT and Hematology and Oncology Associates - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2029-06 |
What NCT05236114 shows while recruiting
NCT05236114 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05236114 names 20 study sites across 11 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05236114 about?
NCT05236114 is a clinical study titled "GEMINI-NSCLC: NSCLC Biomarker Study". GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecula...
What is the current status of trial NCT05236114?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2022-06-22. Estimated completion is 2029-06.
What conditions does trial NCT05236114 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05236114?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05236114?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05236114 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05236114's enrollment target sits among peer trials
1,200 18th of 454 higher than 437 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI